Optimi Health Advances Psilocybin Trial for Depression

Optimi Health (TSE:OPTI) has released an update.

Optimi Health, a manufacturer of psychedelic pharmaceuticals, has received Health Canada’s No Objection Letter to begin a Phase 2 clinical trial of its GMP natural psilocybin capsules, aimed at treating Major Depressive Disorder in frontline mental healthcare workers affected by COVID-19. This milestone marks significant progress for the company’s clinical validation efforts in Canada and holds promise for integrating psilocybin therapy into clinical practice.

For further insights into TSE:OPTI stock, check out TipRanks’ Stock Analysis page.